Because CA-IX is an enzyme overexpressed in cancer and specific inhibitors have been developed, further studies targeting CA-IX should be performed to test the possibility of inhibiting CA-IX function for the treatment of HCC patients. The gene discussed is CA9; the disease is cancer.